Research & Development
Almirall, MC2 Therapeutics Enter a License, Collaboration and Commercialization Agreement for European Rights to Wynzora Cream for treatment of Plaque Psoriasis
18 February 2021 - - Spain-based biopharmaceutical company Almirall S.A. (BME: ALM) and Denmark-based commercial stage pharmaceutical company MC2 Therapeutics have inked an agreement under which MC2 Therapeutics has granted Almirall exclusive European rights to commercialize Wynzora Cream for treatment of plaque psoriasis, the companies said.

In exchange, MC2 Therapeutics is eligible to receive upfront to launch payments of EUR 15m in addition to significant sales milestone payments and double-digit royalties on the European sales of Wynzora Cream.

Almirall and MC2 Therapeutics partner to make Wynzora Cream a leading topical product for treatment of plaque psoriasis in Europe - a market, which currently is more than 25m units in sales volume annually.

The market represents a significant opportunity for Wynzora Cream as the calcipotriene and betamethasone dipropionate segment accounts for approximately 35% of share of volume and annual sales of more than USD 300m.

Wynzora Cream (50 µg/g calcipotriol and 0.5 mg/g betamethasone as dipropionate) received US FDA approval on 20th July 2020. Wynzora Cream is currently under review in Europe supported by two Phase 3 trials, including an EU head-to-head trial against active comparator Dovobet/Daivobet Gel.

The Physician Global Assessment treatment success defined as a minimum two-point decrease in the PGA score to clear or almost clear disease at Week 8 was 51% for Wynzora Cream vs. 6% for vehicle (p